Overall rank by patents
#3,952
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Abiomed Europe Gmbh
USPTO PatentsView assignee record — 91 granted patents across 13 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
91
Total patents granted
13
CPC technology areas
18.4
Avg claims per patent
+558%
5-year filing velocity
The verdict
Abiomed holds 91 US patents across 13 technology areas — rank #3,952 of 50,000 tracked assignees.
- #3,952
- of 50,000 US assignees by volume
- Top 10%
- by Innovation Score (52.5/100)
- 18.4
- avg claims per patent
- +558%
- filing velocity, last 5 yrs
Portfolio overview
Abiomed Europe GmbH has been granted 91 US utility patents between 2016 and 2025, placing Abiomed Europe GmbH at rank #3,952 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.4 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a Foreign Corporation, Abiomed Europe GmbH is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 52.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 79 grants, compared with 12 in the 2015–2019 window — a +558% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Abiomed Europe GmbH's 18.4 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 13 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Abiomed Europe GmbH against peers pursuing similar technology classes.
How does Abiomed compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Abiomed Europe ◀ 91
Abiomed Europe GmbH
91 patents
What this shows Abiomed holds 91 patents — placing it at rank #3,952 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Abiomed's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
52 Top 10% higher than 90% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2016–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 3 | 3.3% |
| 2017 | 6 | 6.6% |
| 2018 | 2 | 2.2% |
| 2019 | 1 | 1.1% |
| 2020 | 9 | 9.9% |
| 2021 | 11 | 12.1% |
| 2022 | 9 | 9.9% |
| 2023 | 17 | 18.7% |
| 2024 | 15 | 16.5% |
| 2025 | 18 | 19.8% |
Which technologies does Abiomed Europe GmbH patent most?
Top 13 of 13 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does Abiomed Europe GmbH hold?
Abiomed Europe GmbH holds 91 US granted patents filed between 2016 and 2025, spanning 13 technology areas.
What is Abiomed Europe GmbH's Innovation Score?
Abiomed Europe GmbH has an Innovation Score of 52.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Abiomed Europe GmbH focus on?
Abiomed Europe GmbH's top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 87 patents. The company has filed patents in 13 CPC subclasses total.
Is Abiomed Europe GmbH's patent filing rate increasing or decreasing?
Abiomed Europe GmbH's recent filing velocity is +558% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Abiomed Europe GmbH's patents?
Abiomed Europe GmbH's patents average 18.4 claims each. This falls within the standard range, providing solid legal coverage.
How is the Abiomed Europe GmbH patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
How to use this portfolio
Abiomed's 91 grants land it in the top 10% by Innovation Score — but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance — Abiomed ranks #3,952 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61M — see who else leads that technology area. A61M leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
A61M technology
Abiomed Europe GmbH's primary CPC class — all holders and yearly trends
Top 50 patent holders
See where Abiomed Europe GmbH ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov
